DMAC — DiaMedica Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1401040 ·
Last close
$7.94
Market Cap
$428.17M
52W High
$10.42
52W Low
$5.24
ADV30
160,400
Next earnings
2026-11-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -10,498,000 | -10,139,000 | 45,001,000 | 5,129,000 | 6,663,000 |
| Mar 2026 | 0 | — | -10,482,000 | -10,042,000 | 53,080,000 | 4,868,000 | 5,845,000 |
| Dec 2025 | 0 | — | -9,213,000 | -8,740,000 | 61,371,000 | 15,647,000 | 5,260,000 |
| Sep 2025 | 0 | — | -9,033,000 | -8,620,000 | 57,047,000 | 3,326,000 | 5,425,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-30,995,000
Investing CF
$-10,928,000
Financing CF
$44,202,000
CapEx
$-36,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.72
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-182,810,000
Inventory
—
Receivables
$301,000
ST Investments
$46,463,000
EBIT TTM
$-36,735,000
Pretax Income TTM
$-35,072,000
Interest Exp TTM
—
Analysts
4
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -34,397,000 | -32,766,000 | 61,371,000 | 5,260,000 | 56,111,000 | -29,062,000 |
| Dec 2024 | 0 | -26,681,000 | -24,444,000 | 46,345,000 | 5,627,000 | 40,718,000 | -22,076,000 |
| Dec 2023 | 0 | -21,267,000 | -19,381,000 | 54,160,000 | 3,103,000 | 51,057,000 | -18,728,000 |
| Dec 2022 | 0 | -14,001,000 | -13,676,000 | 34,395,000 | 2,568,000 | 31,827,000 | -11,511,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.81
Max Pain — expiry 2026-10-16
max pain strike: $5.00 · spot: $8.40 · call oi: 1,508 · put oi: 10Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NIKA | NIKA PHARMACEUTICALS, INC | $429.91M | $0.41 | — |
| PRTA | PROTHENA CORP PUBLIC LTD CO | $425.58M | $8.29 | — |
| AVIR | Atea Pharmaceuticals, Inc. | $414.66M | $5.17 | — |
| CTNM | Contineum Therapeutics, Inc. | $413.96M | $12.56 | — |
| CYPH | CYPHERPUNK TECHNOLOGIES INC. | $443.99M | $4.12 | — |
News headlines (Yahoo Finance, 1h cache)
DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences
2026-09-02 12:30 · Yahoo
Wall Street Analysts Think DiaMedica Therapeutics (DMAC) Could Surge 129.97%: Read This Before Placing a Bet
2026-08-26 13:55 · Yahoo
DiaMedica (DMAC) Q2 2026 Earnings Call Transcript
2026-08-18 01:29 · Yahoo
All You Need to Know About DiaMedica Therapeutics (DMAC) Rating Upgrade to Buy
2026-08-13 16:00 · Yahoo
DiaMedica Therapeutics Inc (DMAC) (Q2 2026) Earnings Call Highlights: Promising Preeclampsia ...
2026-08-11 19:01 · Yahoo
DiaMedica Therapeutics Q2 Earnings Call Highlights
2026-08-11 13:04 · Yahoo
DiaMedica Therapeutics (DMAC): BioTech with Breakthrough Potential
2026-08-03 15:09 · Yahoo
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-17 20:30 · Yahoo
DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction
2026-06-23 12:30 · Yahoo
DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program
2026-06-16 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.